Genmab A/S (GMXAY.PK, GNMSF.OB) said that worldwide net sales of Darzalex, or daratumumab, as reported by Johnson & Johnson (JNJ) were $572 million in 2016. This comprised of net sales of $471 million in the U.S. and net sales in the rest of the world of $101 million.
from RTT - Earnings http://ift.tt/2kd3nTK
via IFTTT
No comments:
Post a Comment